Mitigare® (Colchicine) 0.6 mg Capsules and Authorized Generic Colchicine Capsules may offer an affordable prevention option for your patients with gout. Since 2013, the price of Colcrys® (colchicine, USP) tablets has increased by a total of more than 40%. When you prescribe Mitigare® (Colchicine) 0.6 mg Capsules, adults may have access to the Generic Colchicine Capsule. By lowering the overall cost of treatment, Hikma Specialty USA Inc. is committed to improving patient access to gout flare prophylaxis.

 

Cumulative Price Change of Colchicine Agents for Gout Flare Prevention Since 2013

line graph cumulative price

 

Hikma Specialty USA Inc. Has Helped Save the US Healthcare System ∼$135M*

Launching Mitigare® and Generic Colchicine Capsules changed the dynamics of the colchicine market.2 Prior to launch of Mitigare®, no generic alternatives were available.3 Generic Colchicine Capsules continue to be a lower-priced option.1 Hikma Specialty USA Inc. offers affordable alternatives to branded pharmaceutical products.4

*Total value of colchicine products sold in 2014 vs. 2019. Based on sales data accessed from IQVia® on November 22, 2019.

 

Overall US costs for Colchicine have decreased significantly since the availability of Mitigare® and Generic Colchicine Capsules

bar-graph us costs colchicine

SOURCE: IQVia®. Exported November 22, 2019.

Coverage By Most Major Plans

Mitigare® (Colchicine) 0.6 mg Capsules and Generic Colchicine Capsules are covered by more than 90% of major health plans, including:

  • United Health Group, Inc.
  • Aetna, Inc.
  • CVS Caremark Rx
  • Express Scripts PBM
  • Cigna Health Plans, Inc.
  • CVS SilverScript
  • Most BCBS Plans, State Medicaid and Wellcare Part D

Managed Markets Insight & Technology, LLC database and formulary status as of January 2021. 

To see the latest formulary announcements, see our Managed Care Updates page.

 

The True Blue Savings Program. The ONLY Co-Pay Program for Generic Colchicine Capsules.

Hikma Pharmaceuticals USA Inc. developed the True Blue Savings program for Mitigare® to help make effective gout flare prevention for eligible adults even more affordable. With the Mitigare® True Blue Savings co-pay card, your eligible patients can receive Mitigare® (Colchicine) 0.6 mg Capsules or Generic Colchicine Capsules for as little as $0 for the first 30 days and get $5 refills§.

§For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. First 30 days are as little as $0 only for eligible patients. Maximum savings of $65 on the first fill and $50 on refills. See complete Terms and Conditions

Prescribing Information Recommendations

For healthcare professionals, there are two ways to prescribe Mitigare® (Colchicine) 0.6 mg Capsules and Generic Colchicine Capsules.

 

1

Click Generic Colchicine CAPSULES or Mitigare® in your EMR:

  • Add Mitigare® (Colchicine) 0.6 mg Capsules and Generic Colchicine 0.6 mg Capsules to “My Drug List” and your “Favorites.”
  • Remember: Add DAW Mitigare® or Colchicine 0.6 mg Capsules only in “Notes.”

medication-finder-scaled

 

2
fill a prescription 2019

Write a prescription:

  • If Mitigare® and Generic Colchicine Capsules are not listed in your EMR, ask your Mitigare® sales representative to contact your system administrator.
  • Written prescriptions may be used until your system is updated.

References

  1. First Databank. AnalySource® website. Available at: https://www.analysource.com/. Accessed January 6, 2020.
  2. IQVia® website. Available at: https://www.iqvia.com. Accessed December 2, 2019.
  3. Court allows generic colchicine to enter market. Family Practice News. Available at: https://www.mdedge.com/familypracticenews/article/96726/rheumatology/court-allows-generic-colchicine-enter-market. Accessed December 2, 2019.
  4. Hikma launches first ritonavir generic in USA. the pharmaletter. Available https://www.thepharmaletter.com/article/hikma-launches-first-ritonavir-generic-in-usa. Accessed December 2, 2019.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4.